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a  b  s  t  r  a  c  t
Objective: To assess clinical outcomes of intolerant, relapsed or refractory patients who could
not  be treated with new tyrosine kinase inhibitors or experimental therapies.
Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in all phases of
the  disease treated with imatinib mesylate as their first TKI therapy, and with dasatinib or
nilotinib as the next line of therapy. We  evaluated clinical outcomes of these patients, with
special focus on the group that needed more than two therapy lines.
Results: Thirty-nine percent of patients were refractory or intolerant to imatinib. An 8-year
overall survival rate of the patients who went through three or more lines of treatment
was  significantly lower, compared to those who were able to maintain imatinib as their
first-line therapy (83% and 22%, respectively p < 0.01). Decreased overall survival was asso-
ciated with advanced-phase disease (p < 0.01), failure to achieve major molecular response
in  first-line treatment (p < 0.01) and interruption of first-line treatment due to any reason
(p  = 0.023). Failure in achieving complete cytogenetic response and major molecular response
and treatment interruption were associated with the progression to the third-line treatment.
Conclusion: The critical outcome observed in relapsed, intolerant or refractory chronic phase
CML  patients reflects the unmet need for this group of patients without an alternative ther-
apy,  such as new drugs or experimental therapies in clinical trials. Broader access to newer
treatment possibilities is a crucial asset to improve survival among CML  patients, especially
those refractory or intolerant to first-line therapies.©  2019 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license∗ Corresponding author at: Serviço de Hematologia e Transplante de M
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hronic myeloid leukemia (CML) is a well-identified clonal
yeloproliferative disorder, for which imatinib was the first of
he approved tyrosine kinase inhibitors (TKI). Despite its effec-
iveness, it is estimated that approximately 20% of patients
nitially treated with this drug may be intolerant or may
ecome primary or secondary resistant.1,2 Patients in the
hronic phase who are judged to have experienced treatment
ailure with imatinib, either as a consequence of intolerance
r resistance, are routinely offered treatment with dasa-
inib or nilotinib, known as second-generation TKIs. Another
herapy option is the allogeneic hematopoietic stem cell trans-
lant (HSCT), effective but associated with morbidity.3 In
he absence of an alternative treatment, in our setting, the
ulti-TKI failure chronic-phase CML  patients, without clin-
cal performance or on a waiting list for HSCT, may benefit
rom therapy with interferon. In the long term, however, inter-
eron is associated with a worse clinical outcome and multiple
dverse events.4
New CML  treatment drugs, tested in clinical trials, can be
ffered to rescue-refractory TKIs patients, especially those not
andidates for an HSCT. In Brazil, multinational companies
ere conducting approximately 80% of new medication stud-
es. Even though cancer is currently the national research field
ith the highest number of active studies, none of CML  refrac-
ory TKIs clinical trials were available in our region over the
ast years.5
bjective
he main interest of this study was to assess the CML patient
haracteristics and outcome, especially the patient treated
ith more  than two TKI lines (imatinib, dasatinib or nilotinib),
ithout access to new TKIs or experimental therapies.
ethods
edical records were reviewed, from a retrospective cohort of
0 CML  patients, diagnosed from January 2009, when imatinib
as  released as first-line treatment in Brazil, to October 2017.
ll the patients were treated at Hospital de Clínicas de Porto
legre (HCPA), Brazil.
The analysis included patients in chronic phase (CP), accel-
rated phase (AP) and blast crisis (BC), followed for at least 12
onths, who received imatinib mesylate as their first-line TKI
herapy, and dasatinib or nilotinib as the next line.
Pediatric patients (under 18 years old) and those treated
ith HSCT as second-line treatment were excluded from the
nalysis. The data was analyzed for demographic, clinical and
aboratory data, Sokal score, treatment modality, molecular
esponse (MR), cytogenetic response (CR) and overall survival
OS). Primary resistance was defined as response failure to
he TKI, and secondary resistance was defined as further loss
f response, according to the European Leukemia Net criteria,
LN, version 2009 for patients diagnosed until December
013 and the 2013 version from January 2014.6,7 Treatment
dherence was evaluated through medical or pharmaceutical 0 1 9;4 1(3):222–228 223
records at the patient appointments. Any interruption of
more than 7 days due to any cause, such as nonadherence
and hematologic or non-hematological adverse effect, was
considered.
The data was analyzed using the SPSS Statistics 22.0 and
presented either as absolute or relative frequency, as mean
or median standard error, or as minimum/maximum values,
considering the normality of data distribution. The normality
of variable distribution was assessed with the Shapiro–Wilk’s
test. The Mann–Whitney test was used to compare medi-
ans. Parametric data comparison between groups was made
using the ANOVA. Non-parametric data between groups was
compared using the Kruskal–Wallis test. Categorical variables
were analyzed by using chi-square tests. For comparison of
treatment responses between groups, the McNemar’s test was
used for paired samples. Overall survival distribution was cal-
culated using the Kaplan–Meier test. The log-rank test was
utilized to compare the curves. Differences were considered
significant if p < 0.05.
This study was reviewed and approved by the research
ethics committee at Hospital de Clínicas de Porto Alegre (CAE
52377216.3.0000.5327). The study was conducted in accor-
dance with the provisions of the Declaration of Helsinki and all
experiments described herein comply with the current Brazil-
ian legislation.
Results
A total of 90 CML patients received imatinib as first-line
TKI therapy and the populational baseline characteristics are
described in Figure 1 and Table 1. The median time from diag-
nosis to the introduction of the first-line TKI was 41 days
(14–90 days) and no difference in OS was observed, compar-
ing the patient population that started treatment before or
after 41 days from the diagnosis (88% vs 90%, respectively,
p = 0.64). Thirty-five (38.8%) patients relapsed or were refrac-
tory or intolerant to imatinib, and 13 (14.5%) progressed to
3 or more  lines of treatment. Fifty patients met  the criteria
for optimal response, according to the ELN 20096 recommen-
dations, and five patients, according to the ELN 2013.7 As
for the second-line treatment, the proportions of patients
treated with dasatinib or nilotinib were similar (Figure 1). The
median time to treatment change to a second-line TKI was 290
(63–2139) days. Populational characteristics, according to lines
of treatment, are described in Table 2, including CML  patients
in all disease phases. Not progressing beyond the second line
of treatment was associated with higher rates of complete
cytogenetic response (p = 0.043), with a deeper MR  (p = 0.052)
and no treatment interruption (p = 0.012). Patients in BC had
extremely high mortality.
The total populational overall survival (OS) was 83% in 5
years. The median OS for CP, AP and BC is illustrated in Figure 2
(p < 0.01). Considering solely the CP patients, excluding the
deaths not related to CML, the overall survival rate was 94.5%.
The longest survival rate was observed in the group of CP CML
patients that did not need to change therapy, totalling 86%
in 5 years. The attainment of DNA mismatch repair (MMR)
during the first-line treatment and no treatment interrup-
tion were associated with a significant increase in OS (p < 0.01










































Figure 1 – Chronic myelogenous leukem










to TKI do not carry a BCR/ABL additional mutation, and forAccelerated 6 (6.7)
Blast crisis 3 (3.3)
and p = 0.02, respectively) (Figures 3 and 4). There were only 6
patients in the AP patient group.
In CML, for patients treated with a second line and a third
line and those beyond TKI, the OS in 5 years decreased to 82%
and 77%, respectively (p = 0.01). There was no significant dif-
ference in OS between patients treated with one or two lines
of therapy (Figure 5). From the total population, 13 patients in
CP and AP went through the three available TKIs due to intol-
erance, relapse or lack of response. In the total population,
bone marrow transplantation was feasible just in 2 patients,
and one died from a CML  blast crisis.
Mutation analyses were performed for 17 patients. Eleven
tests were negative and 6 patients presented abnormalities
(2 patients with G250E and an additional mutation: V370I in
one and M351T in the other. The last 4 patients demonstrated
an isolated mutation: T949C, F359C, V299C and F317C). All of
these were resistant to first- or second-line treatment and the
choice of a new drug was based on the mutation analysis.
Discussion
In Brazil, imatinib was approved as a second line after inter-
feron failure or disease progression in 2003 and in the first line
only in 2008. The FDA (Food and Drug Agency) had already
approved the medication in first-line treatment since May
2001 and the EMA  (European Medicines Agency), in Novem-
ber 2001. Dasatinib was available in 2009 and nilotinib in 2010.ia patient therapeutic evolution.
All the results shown in our study should be interpreted with
this bias.
Molecular monitoring of CML patients in complete cytoge-
netic response and the search for mutation analysis in special
situations are recommended by the International Guidelines
(NCCN and ELN2013)7 and the Brazilian Health Ministry. How-
ever, these molecular tests are not available at most public
health care centers due to lack of government funding. In this





) sponsoring. In our real world
scenario, we  are not always able to provide molecular mon-
itoring in the recommended timing. Therefore, this might be
another bias to be considered, such as the late introduction of
second generation TKIs in the second-line treatment.
In this context, the study aims to analyze the clinical char-
acteristics, treatment response and OS in CML, especially in
patients treated after the second line of treatment. Ribeiro
et al. (2015) described 25 consecutive adult CML  patients
who were resistant or intolerant to two  prior TKIs and were
switched to a third TKI, and the OS was comparable to our
results.8 These results may be relevant to other health care
centers that might face the same hurdles in access to clinical
trials and newer drugs.9,10
Complete cytogenetic response, major molecular response
and no treatment interruption were the most impacting fac-
tors in predicting whether patients would be successful in
their first-line treatment. Patients in the CP who required more
than two treatment lines, regardless of the reason: relapse,
intolerance or resistance, had a significantly worse prognosis.
Given the impossibility of including these patients in clini-
cal trials or submitting them to HSCT, many  patients are left
solely with the possibility of palliative care. Ibrahim et al.11
published a large series of cases of CP CML  patients in third-
line TKI therapy, showing that those patients had a failure rate
of 42.3% and a mortality rate 34.6% during the follow-up and
all but one patient died due to a cause not related to CML.
Even though approximately half of the patients refractorymost of them there is not much data regarding the mechanism
of resistance, testing for the mutation is recommended in all
cases that do not meet treatment response milestones.10,12
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Table 2 – Overall populational characteristics, according to the number of treatments needed.
Lines of treatment 1
n = 55
2
n  = 22
3  or more
n = 13
Age (years: median – minimum – maximum) 57.5 (16–99) 56.5 (29–84) 55.5 (28 –83)
Gender (%)
Female 21 (38.2) 8 (36.4) 5 (38.5)
Male 34 (88.8) 14 (63.6) 8 (61.5)
Diagnosis phase (%)
Chronic 50 (90.9) 19 (86.4) 12 (92.3)
Accelerated 5 (9.1) – 1 (7.7)
Blast crisis –  3 (13.6) –
Sokal (%) n  = 52 n  = 21 n  = 13
Low-risk 21 (40.4) 8 (38.1) 5 (38.5)
Intermediate-risk 18 (48.6) 12 (57.1) 7 (53.8)
High-risk 13 (25) 1  (4.8) 1  (7.7)
Complete cytogenetic response – first line (%)b n = 51 n = 20 n = 13
Yes 51 (100) 10 (50) 6 (46.2)
No – 10 (50) 7 (53.8)
Molecular response – first line (%)b n = 50 n = 13 n = 9
≥MMR 49 (98) 5 (38.5) 1 (11.1)
<MMR 1 (2) 8 (61.5) 8 (88.9)
Treatment interruption – first line (%)b n = 54 n = 22 n = 13
Yes 17 (31.5) 13 (59.a) 6 (46.2)
No 37 (68.5) 9 (40.9) 7  (53.8)
Interruption’s reason – first line (%)b n = 17 n = 13 n = 6
Hematological toxicity 4 (23.5) 2 (15.4) 4 (66.7)
Non-hematological toxicity 5 (29.4) 8 (61.5) 1 (16.7)
Othera 8 (47.1) 3 (23.1) 1 (16.7)
MMR: major molecular response.
a Other reasons for interruption refer to lack of medication, patient forgetfulness, pregnancy and surgical procedure. The interruption was
transitory.
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Figure 2 – Cumulative survival, according to the disease stage at diagnosis.


















































Figure 4 – Comparison of survival, according to interruption in the first line of treatment for chronic-phase CML  patients
(missing = 2).
In this study, only 17 patients were tested for mutations, of
whom four were positive. Just like the PCR test for BCR/ABL,
the mutational test is not widely available in the public health
institutions in Brazil, which even further prevents the possi-
bility of providing adequate treatment for these patients.
Although HSCT is currently the only possible manner of
providing the cure for CML, donor availability, ideal referraltiming, in addition to the morbidity and the mortality asso-
ciated with the procedure, are strong limiting factors to this
therapeutic option.13 A Brazilian study shows that, on a long-
term basis, these patients tend to have higher mortality due to
chronic graft-versus-host disease, when compared to patients
treated solely with medication therapy.14 In our study, only
two patients underwent HSCT.










































Figure 5 – Cumulative survival in CML  patients, s
onclusion
he study demonstrated the decrease in the OS of CML
atients, refractory or intolerant to more  than two different
KIs and without access to newer therapies. Presently there
re third-generation TKIs, as well as more  incipient therapies
nvolving cellular therapy with natural killer cells,15 that may
rove to be useful tools to improve the clinical outcomes of
hese patients. This scenario may be modified in the future,
ith new on-going clinical trials. However, it is also equally
mportant that healthcare professionals and public authori-
ies enrolled in the caring for these patients develop strategies
o improve their treatment, minimizing interruptions and pro-
iding adequate response to treatment monitoring.
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